Loading...
Loading...
Also known as: Veoza
A non-hormonal oral treatment for moderate to severe vasomotor symptoms (hot flushes and night sweats) associated with menopause. Fezolinetant is a neurokinin 3 (NK3) receptor antagonist, approved by NICE in 2024. It offers an alternative for women who cannot or prefer not to take HRT.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Total Reports
15
Median Score (Wk 8)
8/10
Would Continue
87%
Avg Duration
11 wk
Most Common Goal
perimenopause
Most Reported Side Effect
Back pain (33%)
Based on self-reported community data. Scores use a 1–10 scale.
Regulatory status does not mean an approach is safe or unsafe. Laws vary by country — check your local regulations.
Women who reported on Fezolinetant mentioned using it for the following goals. This does not mean it is intended for or achieves any of these outcomes.
Aggregated patterns from 15 self-reported experiences with Fezolinetant.
87% of women said they would continue this protocol
7.1/10 average self-reported outcome score at week 8
Most commonly reported effects: Back pain, Insomnia, Abdominal pain, Diarrhoea
Outcome Score Distribution (Week 8)
15 of 15 reports included a week 8 score
Would Continue Protocol
15 of 15 reports included this response
Reported Goals
Commonly Reported Effects
Percentage of reports mentioning each effect
Based on 15 self-reported experiences. This is community data, not clinical evidence. Individual outcomes vary. Discuss any intervention with your healthcare provider.
15 reports from women who tried Fezolinetant
I started Fezolinetant after dealing with irregular periods and mood swings for months. By week 4 I noticed the worst of the symptoms eased. At 10 weeks, my quality of life improved dramatically. Still taking it and plan to continue.
Fezolinetant has been really helpful for my heart palpitations and anxiety. I noticed there was a noticeable difference fairly quickly. my quality of life improved dramatically over the following weeks. Would definitely continue.
I was sceptical about Fezolinetant but desperate with my heavy periods and exhaustion. things started to shift slightly. By week 6, I felt significantly better. Would definitely continue.
My friend who'd been through similar suggested Fezolinetant for my brain fog and fatigue. It took about 3 weeks to notice anything, but by week 12 the difference was remarkable. It's not perfect but it's made a real difference.
I gave Fezolinetant a fair trial for my heavy periods and exhaustion. Some improvement in mood stabilised slightly but sleep didn't improve much persisted. I may try increasing the dose.
Research context compiled from published sources
Selectively blocks neurokinin 3 (NK3) receptors in the hypothalamic thermoregulatory centre (KNDy neurons). Oestrogen decline in menopause leads to overactivity of kisspeptin, neurokinin B, and dynorphin neurons, which dysregulates the thermoneutral zone and triggers hot flushes. By blocking NK3 receptors, fezolinetant restores thermoregulatory stability without affecting oestrogen levels.
Well Studied
Extensive human research over many years, including randomized controlled trials.
Limited
Only short-term data available. Long-term effects are not well understood.
Dose ranges from published research. Individual dosing should be determined with your healthcare provider based on your specific circumstances.
Factual research context from published sources — not a safety assessment or recommendation. Research classifications may change as new data emerges.
Other approaches tracked on Narrated.
Data last updated: March 27, 2026